阿比特龙醋酸酯与恩扎卢胺在未接受化疗的转移性去势抵抗性前列腺癌患者中的真实世界总生存比较
基于Medicare数据库2009至2020年的回顾性分析,纳入5506例未接受化疗的转移性去势抵抗性前列腺癌患者,比较一线阿比特龙(n=2911)与恩扎卢胺(n=2595)的总生存。中位随访分别为19.1个月和20.3个月,IPTW校正后中位OS阿比特龙20.6个月(95%CI 19.7‒21.4) vs 恩扎卢胺22.5个月(95%CI 21.2‒23.8),HR 1.10(95%CI 1.04-1.16)。
要点
- 未接受化疗的转移性去势抵抗性前列腺癌患者中,一线阿比特龙较恩扎卢胺总生存更差,IPTW校正HR 1.10(95%CI 1.04-1.16)。
- ≥75岁、白人、基线合并糖尿病、心血管疾病、糖尿病合并心血管疾病、肾脏疾病及所有社会经济阶层的亚组中,阿比特龙较恩扎卢胺中位OS显著更短。
- 中位随访阿比特龙19.1个月、恩扎卢胺20.3个月。
核心结论
- 在Medicare未接受化疗的转移性去势抵抗性前列腺癌人群中,一线阿比特龙与恩扎卢胺相比总生存更差,在老年和合并症亚组中亦然,支持既往真实世界研究结果并显示结局差异。
研究设计与样本
- 回顾性分析Medicare数据库(2009-2020年),纳入成年男性,需≥1次前列腺癌索赔、转移诊断、无既往化疗或新型激素治疗,并于索引期(2014年9月10日至2017年5月31日)启动一线阿比特龙或恩扎卢胺。
- 共纳入5506例接受一线阿比特龙(n=2911)或恩扎卢胺(n=2595)的患者。
- 采用逆概率治疗加权(IPTW)的Cox比例风险模型比较总生存,并校正基线特征;另按基线特征进行亚组分析。
主要发现
- 中位随访阿比特龙19.1个月,恩扎卢胺20.3个月;IPTW校正后中位OS阿比特龙20.6个月(95%CI 19.7‒21.4) vs 恩扎卢胺22.5个月(95%CI 21.2‒23.8),IPTW校正HR 1.10(95%CI 1.04-1.16)。
- ≥75岁患者中,阿比特龙较恩扎卢胺中位OS显著更短。
- 白人患者中,阿比特龙较恩扎卢胺中位OS显著更短。
- 基线合并糖尿病、心血管疾病、糖尿病合并心血管疾病及肾脏疾病患者中,阿比特龙较恩扎卢胺中位OS显著更短。
- 所有社会经济阶层中,阿比特龙较恩扎卢胺中位OS显著更短。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: There are no large head-to-head phase 3 clinical trials comparing overall survival (OS) for abiraterone and enzalutamide. This study used Medicare claims data to compare OS in patients with chemotherapy-naïve metastatic castration-resistant prostate cancer (mCRPC) who initiated abiraterone or enzalutamide. METHODS: This retrospective analysis of the Medicare database (2009-2020) included adult men with ≥1 claim for prostate cancer, metastatic diagnosis, and no prior chemotherapy or novel hormone therapy who initiated first-line (1L) abiraterone or enzalutamide in the index period (September 10, 2014 to May 31, 2017). Cox proportional-hazards models with inverse probability treatment-weighting (IPTW) were used to compare OS between abiraterone- and enzalutamide-treated patients, adjusting for baseline characteristics. Subgroup analyses by baseline characteristics were also conducted. RESULTS: Overall, 5506 patients who received 1L abiraterone (n = 2911) or enzalutamide (n = 2595) were included. Median follow-up was comparable in both cohorts (abiraterone, 19.1 months; enzalutamide, 20.3 months). IPTW-adjusted median OS (95% CI) was 20.6 months (19.7‒21.4) for abiraterone and 22.5 months (21.2‒23.8) for enzalutamide, with an IPTW-adjusted hazard ratio (95% CI) of 1.10 (1.04-1.16). Median OS was significantly shorter for abiraterone versus enzalutamide in patients ≥75 years old; White patients; patients with baseline diabetes, cardiovascular disease, both diabetes and cardiovascular disease, and renal disease; and across all socioeconomic strata. CONCLUSIONS: In the Medicare chemotherapy-naïve mCRPC population, 1L abiraterone was associated with worse OS versus enzalutamide in the overall population and among subgroups with older age and comorbidities, supporting findings from previous real-world studies and demonstrating a disparity in outcomes.
引用
- George DJ, Ramaswamy K, Yang H, et al. Real-world overall survival with abiraterone acetate versus enzalutamide in chemotherapy-naïve patients with metastatic castration-resistant prostate cancer. Prostate Cancer Prostatic Dis. 2024. PMID: 38538879. doi:10.1038/s41391-024-00816-0
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。